Literature DB >> 8015584

More on the GUSTO trial.

E J Topol, R M Califf, K L Lee.   

Abstract

Mesh:

Substances:

Year:  1994        PMID: 8015584     DOI: 10.1056/NEJM199407283310418

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  Advances in the medical management of acute coronary syndromes.

Authors:  C P Cannon
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Time to Reperfusion: The Critical Modulator in Thrombolysis and Primary Angioplasty.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

3.  Advances in Alliteration in Acute Myocardial Infarction: From "Time to Treatment" to "Onset to Opening"

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

Review 4.  Cost implications of prehospital emergency drug administration. The case of prehospital thrombolytics.

Authors:  S Barton; T Walley
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

5.  Time to Treatment: A Crucial Factor in Thrombolysis and Primary Angioplasty.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 6.  Prehospital thrombolysis: an idea whose time has come.

Authors:  C P Cannon; A J Sayah; R M Walls
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

7.  Time as an Adjunctive Agent to Thrombolytic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

Review 8.  Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.

Authors:  J C Gillis; A J Wagstaff; K L Goa
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

9.  A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.

Authors:  S C Kalish; J H Gurwitz; H M Krumholz; J Avorn
Journal:  J Gen Intern Med       Date:  1995-06       Impact factor: 5.128

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.